Girish K. Srivastava
1 IOBA, Universidad de Valladolid, Valladolid, Spain.
Editorial
Induced pluripotent stem (iPS) cells are a type of stem cell generated by reprogramming adult cells, typically skin cells, through the introduction of specific genes called "reprogramming factors." Among the necessary factors, a combination of four transcription factors (TF) known as OSKM is commonly used. OSKM stands for four-octamer binding protein 34 (OCT3/4), sex-determining region Y-box 2 (SOX2), Kruppel-like factor 4 (KLF4) and cellular myelocytomatosis (MYC). These factors, when introduced into host cells, initiate the reprogramming process. Researchers have proposed more than 30 different combinations of these transcription factors for reprogramming, but only a few combinations have been proven effective for reprogramming somatic cells in both humans and mice. This underscores the complexity and specificity of the reprogramming process, as not all combinations yield successful results. Nevertheless, this reprogramming process allows the cells to revert to a pluripotent state. The factors are usually introduced using nonintegrative or integrative non viral or viral vectors, resetting the gene expression patterns of the adult cells and effectively transforming them into pluripotent stem cells. Pluripotent cells, similar to embryonic stem cells, have the ability to differentiate into various cell types in the body, such as neurons, heart cells, liver cells, and more. Nevertheless, there are some notable drawbacks of iPS technology.
Keywords
iPSC, iPS technology device
References
Al Abbar, A., Ngai, S.C., Nograles, N., Alhaji, S.Y., Abdullah, S., 2020. Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy. Biores Open Access 9, 121–136. https://doi.org/10.1089/biores.2019.0046
de Boni, L., Gasparoni, G., Haubenreich, C., Tierling, S., Schmitt, I., Peitz, M., Koch, P., Walter, J., Wüllner, U., Brüstle, O., 2018. DNA methylation alterations in iPSC- and hESC-derived neurons: potential implications for neurological disease modeling. Clinical Epigenetics 10, 13. https://doi.org/10.1186/s13148-018-0440-0
Fatima, N., Saif Ur Rahman, M., Qasim, M., Ali Ashfaq, U., Ahmed, U., Shareef Masoud, M., 2023. Transcriptional Factors mediated Reprogramming to Pluripotency. Curr Stem Cell Res Ther. https://doi.org/10.2174/1574888X18666230417084518
Lezmi, E., Benvenisty, N., 2022. The Tumorigenic Potential of Human Pluripotent Stem Cells. Stem Cells Transl Med 11, 791–796. https://doi.org/10.1093/stcltm/szac039
Lin, H., Li, Q., Du, Q., Wang, O., Wang, Z., Akert, L., Carlson, M.A., Zhang, C., Subramanian, A., Zhang, C., Lunning, M., Li, M., Lei, Y., 2019. Integrated generation of induced pluripotent stem cells in a low-cost device. Biomaterials 189, 23–36. https://doi.org/10.1016/j.biomaterials.2018.10.027
Liu, S.-P., Fu, R.-H., Huang, Y.-C., Chen, S.-Y., Chien, Y.-J., Hsu, C.Y., Tsai, C.-H., Shyu, W.-C., Lin, S.-Z., 2011. Induced pluripotent stem (iPS) cell research overview. Cell Transplant 20, 15–19. https://doi.org/10.3727/096368910X532828
Puigdevall, P., Jerber, J., Danecek, P., Castellano, S., Kilpinen, H., 2023. Somatic mutations alter the differentiation outcomes of iPSC-derived neurons. Cell Genomics 3, 100280. https://doi.org/10.1016/j.xgen.2023.100280
Son, B., Yoon, H., Ryu, J., Lee, H., Joo, J., Park, H.H., Park, T.H., 2022. Enhanced efficiency of generating human-induced pluripotent stem cells using Lin28-30Kc19 fusion protein. Frontiers in Bioengineering and Biotechnology 10. https://doi.org/10.3389/fbioe.2022.XXXXX
Yamanaka, S., 2020. Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges. Cell Stem Cell 27, 523–531. https://doi.org/10.1016/j.stem.2020.09.014
Yamasaki, S., Sugita, S., Horiuchi, M., Masuda, T., Fujii, S., Makabe, K., Kawasaki, A., Hayashi, T., Kuwahara, A., Kishino, A., Kimura, T., Takahashi, M., Mandai, M., 2021. Low Immunogenicity and Immunosuppressive Properties of Human ESC- and iPSC-Derived Retinas. Stem Cell Reports 16, 851–867. https://doi.org/10.1016/j.stemcr.2021.02.021
Zheng, Y.L., 2016. Some Ethical Concerns About Human Induced Pluripotent Stem Cells. Sci Eng Ethics 22, 1277–1284. https://doi.org/10.1007/s11948-015-9693-6
World Health Organization (online) (assessed Nov. 08, 2022). Available from https://www.who.int/health-topics/medical-devices#tab=tab_1
Publication
Received: 01/12/2022
Accepted: 07/12/2022
Published: 31/12/2022
DOI: 10.64307/allbiosolutionA0401020
Citation
Srivastava GK. Disadvantages of iPS Technology. Journal of AllBioSolution. 2022;4(1):201–203. doi:10.64307/allbiosolutionA0401020